NCT06905509
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +23 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Clinical trial condition
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Explore clinical trials studying Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements. Study availability and eligibility vary by location and protocol.
3 public trials
2 recruiting studies
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements trial results
NCT06834373
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +39 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota, United States
- Mayo Clinic Health Systems-Mankato Mankato, Minnesota, United States
Not Yet Recruiting
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
NCT07724457
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +18 more
- Locations
-
Not specified